160 related articles for article (PubMed ID: 21178264)
1. Serum thymidine kinase 1 activity in breast cancer.
Nisman B; Allweis T; Kaduri L; Maly B; Gronowitz S; Hamburger T; Peretz T
Cancer Biomark; 2010; 7(2):65-72. PubMed ID: 21178264
[TBL] [Abstract][Full Text] [Related]
2. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients.
Nisman B; Allweis T; Kadouri L; Mali B; Hamburger T; Baras M; Gronowitz S; Peretz T
Clin Chem Lab Med; 2013 Feb; 51(2):439-47. PubMed ID: 23093267
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
Nisman B; Yutkin V; Nechushtan H; Gofrit ON; Peretz T; Gronowitz S; Pode D
Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
[TBL] [Abstract][Full Text] [Related]
4. Relationship between thymidine kinase 1 before radiotherapy and prognosis in breast cancer patients with diabetes.
Wang Z; Zhang W; Huo B; Dong L; Zhang J
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32202305
[TBL] [Abstract][Full Text] [Related]
5. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
[TBL] [Abstract][Full Text] [Related]
6. Can thymidine kinase levels in breast tumors predict disease recurrence?
O'Neill KL; Hoper M; Odling-Smee GW
J Natl Cancer Inst; 1992 Dec; 84(23):1825-8. PubMed ID: 1433372
[TBL] [Abstract][Full Text] [Related]
7. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer.
He Q; Fornander T; Johansson H; Johansson U; Hu GZ; Rutqvist LE; Skog S
Anticancer Res; 2006; 26(6C):4753-9. PubMed ID: 17214336
[TBL] [Abstract][Full Text] [Related]
8. Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial.
Bjöhle J; Bergqvist J; Gronowitz JS; Johansson H; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Söderberg M; Sundquist M; Walz TM; Fernö M; Bergh J; Hatschek T
Breast Cancer Res Treat; 2013 Jun; 139(3):751-8. PubMed ID: 23736998
[TBL] [Abstract][Full Text] [Related]
9. A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease.
Kumar JK; Aronsson AC; Pilko G; Zupan M; Kumer K; Fabjan T; Osredkar J; Eriksson S
Tumour Biol; 2016 Sep; 37(9):11937-11945. PubMed ID: 27079872
[TBL] [Abstract][Full Text] [Related]
10. Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer.
Elfagieh M; Abdalla F; Gliwan A; Boder J; Nichols W; Buhmeida A
Tumour Biol; 2012 Dec; 33(6):2371-7. PubMed ID: 22948780
[TBL] [Abstract][Full Text] [Related]
11. Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker.
Jagarlamudi KK; Hansson LO; Eriksson S
BMC Cancer; 2015 Feb; 15():66. PubMed ID: 25881026
[TBL] [Abstract][Full Text] [Related]
12. Thymidine kinase 1 expression in ovarian serous adenocarcinoma is superior to Ki-67: A new prognostic biomarker.
Wang J; Liu Q; Zhou X; He Y; Guo Q; Shi Q; Eriksson S; Zhou J; He E; Skog S
Tumour Biol; 2017 Jun; 39(6):1010428317706479. PubMed ID: 28651488
[TBL] [Abstract][Full Text] [Related]
13. Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report.
Nisman B; Nechushtan H; Biran H; Gantz-Sorotsky H; Peled N; Gronowitz S; Peretz T
J Thorac Oncol; 2014 Oct; 9(10):1568-72. PubMed ID: 25521401
[TBL] [Abstract][Full Text] [Related]
14. Serum Concentration of Thymidine Kinase 1 (TK1) as a Tumor Marker in Soft Tissue Sarcomas.
Jaamaa S; Nevala R; Jagarlamudi K; Tukiainen E; Blomqvist C; Sampo M
Anticancer Res; 2022 Mar; 42(3):1509-1515. PubMed ID: 35220246
[TBL] [Abstract][Full Text] [Related]
15. The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody.
He Q; Zou L; Zhang PA; Lui JX; Skog S; Fornander T
Int J Biol Markers; 2000; 15(2):139-46. PubMed ID: 10883887
[TBL] [Abstract][Full Text] [Related]
16. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity.
He Q; Zhang P; Zou L; Li H; Wang X; Zhou S; Fornander T; Skog S
Oncol Rep; 2005 Oct; 14(4):1013-9. PubMed ID: 16142366
[TBL] [Abstract][Full Text] [Related]
17. High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma.
Procházka V; Faber E; Raida L; Langová K; Indrák K; Papajík T
Leuk Lymphoma; 2012 Jul; 53(7):1306-10. PubMed ID: 22263569
[TBL] [Abstract][Full Text] [Related]
18. Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer.
Matikas A; Wang K; Lagoudaki E; Acs B; Zerdes I; Hartman J; Azavedo E; Bjöhle J; Carlsson L; Einbeigi Z; Hedenfalk I; Hellström M; Lekberg T; Loman N; Saracco A; von Wachenfeldt A; Rotstein S; Bergqvist M; Bergh J; Hatschek T; Foukakis T
ESMO Open; 2021 Apr; 6(2):100076. PubMed ID: 33714010
[TBL] [Abstract][Full Text] [Related]
19. Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial.
McCartney A; Bonechi M; De Luca F; Biagioni C; Curigliano G; Moretti E; Minisini AM; Bergqvist M; Benelli M; Migliaccio I; Galardi F; Risi E; De Santo I; Romagnoli D; Biganzoli L; Di Leo A; Malorni L
Clin Cancer Res; 2020 May; 26(9):2131-2139. PubMed ID: 31937617
[TBL] [Abstract][Full Text] [Related]
20. Clinical Applicability of the Proliferation Marker Thymidine Kinase 1 in Head and Neck Cancer Patients.
Meirovitz A; Gross M; Leibovici V; Sheva K; Popovzer A; Barak V
Anticancer Res; 2021 Feb; 41(2):1083-1087. PubMed ID: 33517319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
